Survival was significantly improved for patients with hormone receptor–positive tumors.
Multiple large clinical trials have shown that early clinical response to preoperative chemotherapy correlates with pathologic response at the time of surgery and overall survival. Now, German Breast Group researchers have conducted a prospective, phase III trial (GeparTrio) to evaluate response-guided neoadjuvant chemotherapy in 2072 patients with histologic confirmation of breast cancer. Patients also had ≥1 of the following risk factors: age <36, clinical tumor size >5 cm, estrogen receptor (ER) and progesterone receptor (PR) negativity, clinical axillary node involvement, or undifferentiated tumor grade. Patients with features of locally advanced breast cancer, including inflammatory breast cancer, were allowed.
The 1390 responders to an…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)